S&P TEST

SWOT & PESTLE.com

ABBVIE SWOT & PESTLE ANALYSIS

© Barakaat Consulting - An Ezzy IT Consulting Business

This is a licensed product and is not to be photocopied or distributed. All rights reserved. Unauthorized reproduction is strictly prohibited. Research is based on best available materials and resources. Topurchase reprints of this document, please email support@swotandpestle.com.



Company Name: AbbVie

Company Sector: Bio-pharmaceutical

Operating Geography: USA, North America, Global

About the Company:

AbbVie is a bio-pharmaceutical multinational founded in 2013 as a spin-off from Abbot, headquartered in North Chicago, Illinois. It manufactures a wide range of pharmaceutical products which are mainly instrumental in the treatment of diseases like HIV, HCV, Parkinson's disease, thyroid diseases, cancer etc. It has a worldwide presence consisting of nearly 50,000 employees as of early 2023, which includes scientists, manufacturing experts, and researchers in 70 countries. The company has taken upon itself the onus of curing seemingly 'incurable' diseases so that it ultimately creates a positive impact on the lives of the patients. Organizations like 'World's Best Workplaces', 'ROBECOSAM', 'FTSE4Good' and 'Fortune 100 Best Companies to Work for' have recognized AbbVie for their monumental effort to create a healthier world and care for stakeholders. In March 2022, AbbVie successfully acquired Syndesi Therapeutics SA, which will aid in the expansion of AbbVie's portfolio of neurological products.

The USP of AbbVie lies in its innovative capabilities which led to the development of the drug Humira and made the company a global pharma giant. AbbVie's mission as per their website is to "Create an innovation-driven, patient-focused specialty biopharmaceutical company capable of achieving sustainable top-tier performance through outstanding execution and a consistent stream of innovative new medicines."

Revenue:

US \$58 billion - FY ended December 31, 2022

US \$56.2 billion - FY ended December 31, 2021



SWOT Analysis:

The SWOT Analysis for AbbVie is given below:

Strengths	Weaknesses
1.Strong manufacturing capabilities with state-	1.Public relations issues regarding products
of-art facilities	2.High reliance on revenues from top-selling
2.Diversified products and innovation	monoclonal antibody, Humira
3.Strong supplier relations and reliability	3.Weak corporate governance leading to
4.Strong focus on sustainability through	concerns amongst investors
'Sustainable supply chain'	
5.Strong and robust technological capabilities	
6.Robust pipeline of growth and development	
Opportunities	Threats
Opportunities 1.Remarkable growth potential in the next	Threats 1.Increasing risks from biosimilars
1.Remarkable growth potential in the next	1.Increasing risks from biosimilars
1.Remarkable growth potential in the next decade	1.Increasing risks from biosimilars 2.Strong competition in the pharma segment
1.Remarkable growth potential in the next decade 2.Growing pharmaceutical market in the	1.Increasing risks from biosimilars2.Strong competition in the pharma segment3.Government regulations regarding
1.Remarkable growth potential in the next decade 2.Growing pharmaceutical market in the emerging economies	1.Increasing risks from biosimilars 2.Strong competition in the pharma segment 3.Government regulations regarding Medicare/Medicaid payments
1.Remarkable growth potential in the next decade 2.Growing pharmaceutical market in the emerging economies 3.Covid 19 pandemic triggered improved	1.Increasing risks from biosimilars 2.Strong competition in the pharma segment 3.Government regulations regarding Medicare/Medicaid payments



PESTLE Analysis:

The PESTLE Analysis for AbbVie is given below:

Political	Economical
1.Customs trade partnership against Terrorism	1.Risk of unemployed, uninsured and
2.Lobbying against efforts at price controls	underinsured people
	2.Government funding of pharmaceutical R&D
Social	Technological
1.Patient criticism for high drug prices	1.Technological development by AbbVie
2.Targeting local needs and establishing an	competitors
overarching access strategy	2.Leveraging innovative technologies and
	platforms
Legal	Environmental
1.Increasing regulations on pharmaceutical	1.Initiatives to combat climate change
companies	
2.Data protection and employee privacy	

Please note that our free summary reports contain the SWOT and PESTLE table contents only. The complete report for **AbbVie** SWOT & PESTLE Analysis is a paid report at **12.53 U.S.D.**



* By clicking on "Buy Now" you agree to accept our "Terms and Conditions."

S&P SWOT & PESTLE.com

SWOT & PESTLE.com is a leading strategy research portal covering detailed Strengths, Weaknesses, Opportunities, Threats (SWOT) and Political, Economic, Social, Technological, Legal and Environmental (PESTLE) analysis of leading industry sectors and organizations across the globe. Our full and comprehensive collection on SWOT and PESTLE has been written by our team of professional analysts consisting of MBA's, CFA's and industry experts. Our analysis has helped businesses, researchers and scholars with valuable insights to make strategic decisions and take their research forward.

We at SWOT & PESTLE.com aim to aid the understanding of the multifaceted business world by presenting a list of diverse companies from across the globe. Business organizations today cannot function in ways that ignore the surroundings that they are set in. SWOT & PESTLE.com makes a keen observation into this aspect and accounts for factors affecting such businesses.

Copyright Notice

The information provided in the SWOT and PESTLE research reports on www.swotandpestle.com are from publicly available documents and sources which are deemed reliable. Further the reports contain analysis and views from the SWOT & PESTLE.com research and analyst team which consists of qualified experts. While every attempt has been made to ensure completeness, accuracy and reliability of the analysis, Barakaat Consulting and its associate websites cannot be held responsible or legal liable for omissions or errors in our reports or on any of our pages.

(C)2024 Barakaat Consulting. All rights reserved. This report may not be reproduced, copied or redistributed, in whole or in part, in any form or by any means, without the express written consent of Barakaat Consulting. Also, Barakaat Consulting is the sole copyright owner of this report, and any use of this report by any third party is strictly prohibited without a license expressly granted by Barakaat Consulting. Neither all nor any part of the contents of this report, or any opinions expressed herein, can be used in advertising, press releases, or promotional materials without prior written approval from Barakaat Consulting. Any violation of Barakaat Consultings rights in this report will be executed to the fullest extent of the law, including the pursuit of monetary damages and injunctive relief in the event of any breach of the foregoing restrictions.

Client Support: support@swotandpestle.com